Short Interest in Lyell Immunopharma, Inc. (NASDAQ:LYEL) Drops By 26.1%

Lyell Immunopharma, Inc. (NASDAQ:LYEL) was the recipient of a significant decline in short interest during the month of March. As of March 15th, there was short interest totalling 5,980,000 shares, a decline of 26.1% from the February 28th total of 8,090,000 shares. Based on an average daily volume of 1,090,000 shares, the days-to-cover ratio is currently 5.5 days. Currently, 4.8% of the company’s shares are short sold.

Lyell Immunopharma Stock Down 0.6 %

Shares of NASDAQ:LYEL traded down $0.00 during midday trading on Monday, reaching $0.54. The company’s stock had a trading volume of 869,624 shares, compared to its average volume of 1,059,509. Lyell Immunopharma has a 12-month low of $0.48 and a 12-month high of $3.15. The firm has a market capitalization of $158.83 million, a P/E ratio of -0.68 and a beta of -0.41. The firm has a 50 day moving average of $0.61 and a 200-day moving average of $0.86.

Lyell Immunopharma (NASDAQ:LYEL) last posted its quarterly earnings results on Wednesday, March 12th. The company reported ($0.72) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.52). The company had revenue of $0.01 million during the quarter. Lyell Immunopharma had a negative return on equity of 34.64% and a negative net margin of 323,792.09%. On average, research analysts predict that Lyell Immunopharma will post -0.78 EPS for the current year.

Insider Buying and Selling at Lyell Immunopharma

In other Lyell Immunopharma news, Director Richard Klausner purchased 158,000 shares of Lyell Immunopharma stock in a transaction that occurred on Friday, March 14th. The shares were bought at an average price of $0.60 per share, for a total transaction of $94,800.00. Following the acquisition, the director now directly owns 843,365 shares in the company, valued at approximately $506,019. This trade represents a 23.05 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Lynn Seely bought 175,000 shares of the firm’s stock in a transaction that occurred on Friday, March 14th. The shares were acquired at an average price of $0.61 per share, with a total value of $106,750.00. Following the acquisition, the chief executive officer now owns 712,500 shares of the company’s stock, valued at $434,625. This represents a 32.56 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last 90 days, insiders purchased 733,000 shares of company stock worth $429,550. 25.10% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Intech Investment Management LLC bought a new position in Lyell Immunopharma in the 3rd quarter valued at approximately $52,000. Erste Asset Management GmbH bought a new position in shares of Lyell Immunopharma during the third quarter valued at $82,000. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Lyell Immunopharma during the third quarter valued at $52,000. Centiva Capital LP bought a new stake in Lyell Immunopharma in the 3rd quarter worth about $31,000. Finally, State Street Corp raised its position in Lyell Immunopharma by 1.9% in the 3rd quarter. State Street Corp now owns 3,889,553 shares of the company’s stock worth $5,368,000 after buying an additional 71,233 shares during the last quarter. Institutional investors own 66.05% of the company’s stock.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a “neutral” rating and set a $1.00 target price on shares of Lyell Immunopharma in a report on Thursday, March 13th.

About Lyell Immunopharma

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.